Cited by 19Liver Diseases and ImmunityLiver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases

Corpechot, Christophe·2016·Clinics in Liver Disease

Abstract

Methods of liver fibrosis assessment have changed considerably in the last 20 years, and noninvasive markers now have been recognized as major first-line tools in the management of patients with chronic viral hepatitis infection. But what about the efficiency and utility of these surrogate indices for the more uncommon chronic cholestatic liver diseases, namely primary biliary cirrhosis and primary sclerosing cholangitis? This article provides clinicians with a global overview of what is currently known in the field. Both diagnostic and prognostic aspects of noninvasive markers of fibrosis in cholestatic liver diseases are presented and discussed.

Integrity signals

Registry

Crossref · 10.1016/j.cld.2015.08.013

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Liver stiffness measurement (LSM), assessed by vibration-controlled transient elastography (VCTE), has been shown as one of the best surrogate markers for the detection of cirrhosis or severe fibrosis (ie, bridging fibrosis) in patients with PBC.

    “Liver stiffness measurement (LSM), assessed by vibration-controlled transient elastography (VCTE), has been shown as one of the best surrogate markers for the detection of cirrhosis or severe fibrosis (ie, bridging fibrosis) in patients with PBC.107 220”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Corpechot, C.
Affiliations
Inserm (FR)
Corresponding author
Corpechot, Christophe
Venue
Clinics in Liver Disease
Publisher
Elsevier BV
Published
2016-02
Volume
20
Issue
1
Pages
143-158
ISSN
1089-3261 (ISSN-L)
OpenAlex
W2161873403
Cited by
19
References
75
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2022: 1 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 1
FWCI
0.29
Type
journal article
Language
en
Open access
closed
Locations
  • Clinics in Liver Disease (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
liver fibrosis, non-invasive fibrosis markers, cholestatic liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, chronic viral hepatitis, fibrosis staging, prognosis, diagnosis
MeSH terms
Biopsy, Humans, Liver, Liver Cirrhosis, Liver Cirrhosis, Biliary, Magnetic Resonance Imaging, Prognosis, Cholangitis, Sclerosing, Biomarkers, Elasticity Imaging Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review